Pneumococcal vaccine in patients with idiopathic juvenile arthritis in treatment with tumor necrosis factor inhibitors

Main Article Content

Javiera Berho
María-Paulina Monsalvez
Jaime Inostroza
Jorge Rojas
Arnoldo Quezada

Keywords

adalimumab, etanercept, immunosuppressive drugs, juvenile idiopathic arthritis, monoclonal antibodies, pneumococcal vaccine

Abstract

Introduction: Juvenile idiopathic arthritis (JIA) is the most common rheumatological disease of childhood. The therapy with tumor necrosis factor (TNF) inhibitors (TNFi) in JIA patients has demonstrated efficacy and safety. The most reported adverse event is the high susceptibility to infections. Preventive vaccination helps to decrease these risks. The information on response to vaccines in JIA patients having treatment with anti-TNF is limited.
Objectives: To evaluate the response to pneumococcal vaccine in JIA patients undergoing treatment with mAb.
Materials and methods: Analytical observational mixed cohort study. Data obtained from the clinical records of an immunorheumatology polyclinic of a metropolitan hospital in Santiago (Chile). Treatments, pneumococcal vaccine schedules, immunological laboratory, and measurement of specific antibodies against 10 pneumococcal serotypes were recorded.
Results: Nineteen patients were included; average age was 13.8 years; and average evolution time of the disease was 46.2 months. Adalimumab (Humira®) was indicated in case of 13 patients (68.4%) and etanercept (Enbrel®) to 6 (31.5%). The most indicated scheme was a dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed at 8 weeks by a dose of pneumococcal polysaccharide vaccine (PPSV23) in nine (47.3%) patients. Seventeen (89.4%) patients were on immunosuppressive treatment at the time of vaccination. Only one patient did not meet the criteria for response to vaccine.
Conclusions: The pneumococcal vaccine induces protective levels of serum antibodies in JIA patients undergoing TNFi treatment. The vaccination schedule and the lymphocyte count could influence the response capacity.

Abstract 93 | PDF Downloads 65 XML Downloads 3 HTML Downloads 11

References

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377: 2138–49. https://doi.org/10.1016/S0140-
6736(11)60244-4
2. Palman J, Shoop-Worrall S, Hyrich K, McDonagh JE. Update on the epidemiology, risk factors and disease outcomes of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2018 Apr;32(2):206–222. https://doi.org/10.1016/j.berh.2018.10.004
3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–2. PMID: 14760812.
4. Blazina S, Markelj G, Avramovic MZ, Toplak N, Avcin T. Management of juvenile idiopathic arthritis: A clinical guide. Pediatr Drugs. 2016;18:397–412. https://doi.org/10.1007/s40272-016-0186-0
5. Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: A narrative review. Eur J Pediatr. 2017;176:1147–53. https://doi.org/10.1007/s00431-017-2960-6
6. Davies HD, AAP Committee on Infectious Diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2):e20161209. https://doi.org/10.1542/peds.2016-1209
7. Diener C, Horneff G. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: A systematic review. Expert Opin Drug Saf. 2019;18:8719–32. https://doi.org/10.1080/14740338.2019.1632288
8. Lee WJ, Lee TA, Suda KJ, Calip GS, Briars L, Schumock GT. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. Rheumatology. 2018;57:273–82. https://doi.org/10.1093/rheumatology/kex049
9. Gluck T, Kiefmann B, Grohmann M, Falk W, Straub RH, Scholmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32:1473–80. PMID: 16078322
10. Nagy A, Mátrai P, Hegyi P, Alizadeh H, Bajor J, Czopf L et al. The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: A meta-analysis. Ped Rheumatol. 2019;17:4. https://doi.org/10.1186/s12969-019-0305-x
11. Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–12. https://doi.org/10.1136/ard.2011.150193
12. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimm Rev. 2008;8(2):124–8. https://doi.org/10.1016/j.autrev.2008.07.007
13. Morin MP, Quach C, Fortin E, Chédeville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012 Nov;51(11):2046–50. https://doi.org/10.1093/rheumatology/kes175
14. Sousa S, Duarte AC, Cordeiro I, Ferreira J, Gonçalves MJ, Meirinhos T et al. Efficacy and safety of vaccination in pediatric patients with systemic inflammatory rheumatic diseases: A systematic review of the literature. Acta Reumatol Port. 2017;42:8–16.
15. Martire B, Azzari Ch, Badolato R, Canessa C, Cirillo E, Gallo V et al. Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). Vaccine. 2018;36:3541–54. https://doi.org/10.1016/j.vaccine.2018.01.061
16. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018 Sep 18;36(39):5832–45. https://doi.org/10.1016/j.vaccine.2018.07.039
17. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou-Gertsi P, Tritsoni M et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 2010;28:5109–13. https://doi.org/10.1016/j.vaccine.2010.03.080
18. Lipsitch M, Li LM, Patterson S, Trammel J, Juergens C, Gruber WC, et al. Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. Vaccine. 2018 Jan 25;36(4):473–8. https://doi.org/10.1016/j.vaccine.2017.12.015
19. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009 Oct 31;374(9700):1543–56. PMID: 19880020. https://doi.org/10.1016/S0140-6736(09)61114-4
20. Vernatter J, Pirofski LA. Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis. 2013 Jun;26(3):277–83. https://doi.org/10.1097/QCO.0b013e3283608419
21. Kuronuma K, Takahashi H. Immunogenicity of pneumococcal vaccines in comorbid autoimmune and chronic respiratory diseases. Hum Vaccin Immunother. 2019;15(4):859–62. https://doi.org/10.1080/21645515.2018.1564443
22. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521–4.
23. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement–Immunization for streptococcus pneumoniae infections in high-risk children. Pediatrics. 2015 May;135(5):945. https://doi.org/10.1542/peds.2015-0451
24. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years. CDC 2019 [Internet]. Available from: https://www.cdc.gov/vaccines/schedules/downloads/past/2019.pdf Accessed on October 13, 2020.
25. Quezada A, Maggi L, Norambuena X, Inostroza J, Quevedo F. Response to pneumococcal polysaccharide vaccine in children with asthma, and children with recurrent respiratory infections, and healthy children. Allergol Immunopathol. 2016;44(4):376–81. https://doi.org/10.1016/j.aller.2016.01.003
26. Taddio A, Cattalini C, Simonini G, Cimaz R. Recent advances in the use of anti-TNFα therapy for the treatment of juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2016;12(6):641-49. https://doi.org/10.1586/1744666X.2016.1146132
27. Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmun Rev. 2017;16:1008–1015. https://doi.org/10.1016/j.autrev.2017.07.014
28. Aikawa NE, França ILA, Ribeiro AC, Sallum AME, Bonfa E, Silva CA. Short- and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine 2015;33:604–9. https://doi.org/10.1016/j.vaccine.2014.12.030
29. Broyde A, Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D et al. Long-term efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol. 2016 Feb;43(2):267–72. https://doi.org/10.3899/jrheum.150397
30. Rakoczi E, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3:e000484. https://doi.org/10.1136/rmdopen-2017-000484